Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL237694 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3982932-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | Dnalite Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| CN-113455645-A | Food formula beneficial to human body health and preparation process | 陈瀚麟 | 2021-10-01 | — | — | CN | claimed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | claimed |
| EP-2799087-B1 | Method and device for producing optimized lipid-based micro/nano-bubbles | TRUST BIO SONICS INC (TW) | 2020-03-11 | — | — | EP | claimed |
| US-20250268839-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2025-08-28 | — | — | US | disclosed |
| US-12203022-B2 | Formulations for high selective silicon nitride etch | ENTEGRIS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| CN-119263731-A | Large-particle recycled aggregate concrete and preparation method thereof | 青岛建一混凝土有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4370099-A1 | METHODS FOR PREPARING LIPOSOMAL FORMULATIONS | Celator Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023230587-A2 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF | AKAGERA MEDICINES, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230355537-A1 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM (NL) | 2023-11-09 | — | — | US | disclosed |
| CN-114960239-B | Preparation method and application of printing and dyeing dye | 吴江市永前纺织印染有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-113455645-A | Food formula beneficial to human body health and preparation process | 陈瀚麟 | 2021-10-01 | — | — | CN | disclosed |
| WO-2021112932-A2 | IMPROVED FORMULATIONS FOR HIGH SELECTIVE SILICON NITRIDE ETCH | ENTEGRIS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210102956-A1 | ASSAY FOR hERG CHANNEL SENSITIVITY TO SMALL MOLECULE PHARMACOLOGICAL AGENTS | UNIV ROCKEFELLER (US) | 2021-04-08 | — | — | US | disclosed |
| US-20210054287-A1 | FORMULATIONS FOR HIGH SELECTIVE SILICON NITRIDE ETCH | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2021-02-25 | — | — | US | disclosed |
| WO-2020252375-A1 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | DNALITE THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3672618-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS | Nal Pharmaceutical Group Limited (HK) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040282-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS | NAL PHARMACEUTICAL GROUP LIMITED (CN) | 2019-02-28 | — | — | WO | disclosed |
| CN-107727755-A | A kind of detection method of phosphatidylserine | 南通励成生物工程有限公司 | 2018-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381303-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | PHOSPHO1, PTDSS1, PTDSS2 | P2RY10 3145/4885GPR34 3647/4885GPR174 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.